Valiant Laboratories Limited
NSE: VALIANTLAB · Pharmaceuticals
Snapshot
Unlock Valiant Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Valiant Laboratories Limited is an Indian pharmaceutical company primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs). The company specialises in the production of paracetamol API and associated finished dosage forms, including tablets and capsules.
Business Model
The company generates revenue through the large-scale manufacturing and sale of paracetamol-based pharmaceutical products. It operates as a supplier within the healthcare value chain, catering to the demand for essential pain and fever management medications.
Growth Outlook
Growth is primarily driven by the sustained demand for paracetamol as a fundamental analgesic and antipyretic medication. The company focuses on maintaining its manufacturing capabilities to serve the broader pharmaceutical market.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards which, if breached, could lead to operational disruptions.
- Commodity Price Volatility. Fluctuations in the cost of raw materials and chemical inputs can significantly impact profit margins.
- Market Competition. The API manufacturing sector is highly competitive, with pricing pressures from both domestic and international players.
- Product Concentration. Heavy reliance on a single core product, paracetamol, exposes the company to risks associated with changes in demand or therapeutic preferences for that specific ingredient.
Start your research today
Unlock AI insights, financials, peers and live data on Valiant Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹306 Cr
TTM · consolidated
NET PROFIT
₹16 Cr
TTM · consolidated
EPS
₹2.95
TTM · consolidated
RETURN ON EQUITY
5.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.0%
TTM · consolidated
P/E
42.4x
Q1 FY27 · consolidated
EV/EBITDA
19.6x
Q1 FY27 · consolidated
EBITDA MARGIN
11.7%
TTM · consolidated
NET PROFIT MARGIN
18.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Valiant Laboratories LimitedVALIANTLAB | ₹658 Cr | 42.40 | 19.55 | 89.6% | 11.7% | 5.9% | 8.0% | +50.1% |
Bafna Pharmaceuticals LimitedBAFNAPH | ₹796 Cr | 115.12 | 46.63 | -3.1% | 12.5% | 8.6% | 10.3% | +119.3% |
Kilitch Drugs (India) LimitedKILITCH | ₹775 Cr | 17.43 | 17.72 | 14.0% | 20.2% | 12.1% | 15.6% | -36.5% |
Amanta HealthcarAMANTA | ₹735 Cr | 45.77 | 14.20 | — | 21.5% | 6.7% | 9.9% | +39.7% |
Zim LaboratoriesZIMLAB | ₹715 Cr | 167.10 | 20.79 | 7.6% | 9.9% | 1.3% | 5.7% | +91.2% |
Influx Health.INFLUX | ₹655 Cr | — | — | — | 20.0% | — | — | +51.5% |
As of Q1 FY27
Financials
Valiant Laboratories Limited
NSE: VALIANTLAB · Pharmaceuticals
Snapshot
Unlock Valiant Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Valiant Laboratories Limited is an Indian pharmaceutical company primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs). The company specialises in the production of paracetamol API and associated finished dosage forms, including tablets and capsules.
Business Model
The company generates revenue through the large-scale manufacturing and sale of paracetamol-based pharmaceutical products. It operates as a supplier within the healthcare value chain, catering to the demand for essential pain and fever management medications.
Growth Outlook
Growth is primarily driven by the sustained demand for paracetamol as a fundamental analgesic and antipyretic medication. The company focuses on maintaining its manufacturing capabilities to serve the broader pharmaceutical market.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards which, if breached, could lead to operational disruptions.
- Commodity Price Volatility. Fluctuations in the cost of raw materials and chemical inputs can significantly impact profit margins.
- Market Competition. The API manufacturing sector is highly competitive, with pricing pressures from both domestic and international players.
- Product Concentration. Heavy reliance on a single core product, paracetamol, exposes the company to risks associated with changes in demand or therapeutic preferences for that specific ingredient.
Start your research today
Unlock AI insights, financials, peers and live data on Valiant Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹306 Cr
TTM · consolidated
NET PROFIT
₹16 Cr
TTM · consolidated
EPS
₹2.95
TTM · consolidated
RETURN ON EQUITY
5.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.0%
TTM · consolidated
P/E
42.4x
Q1 FY27 · consolidated
EV/EBITDA
19.6x
Q1 FY27 · consolidated
EBITDA MARGIN
11.7%
TTM · consolidated
NET PROFIT MARGIN
18.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27